Skip to content
Unrated Drug recall · FDA · Published April 24, 2019

Legacy Pharmaceutical Losartan Tablets Recall: NMBA Impurity Risk

Legacy Pharmaceutical Packaging LLC recalls 50mg Losartan Potassium Tablets due to trace NMBA impurity detected in the active ingredient. This may pose health risks. Consumers should contact the manufacturer for details.

🇺🇸 FDA recall #D-1263-2019DrugLegacy Pharmaceutical Packaging LLC ›
Take action

Contact the company

Recalling firmLegacy Pharmaceutical Packaging LLC13333 Lakefront Dr · Earth City, MO 63045-1514
✎ GovInfoNow plain-language explainer

What happened, in plain English

Legacy Pharmaceutical Packaging LLC is recalling 50mg Losartan Potassium Tablets because trace amounts of a potentially harmful chemical called NMBA were found in the active ingredient. This recall is for prescription-only bottles distributed by The Kroger Co. Read more at govinfonow.com/recall/38880-legacy-pharmaceutical-losartan-tablets-recall-nmba-impurity-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/38880-legacy-pharmaceutical-losartan-tablets-recall-nmba-impurity-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-1263-2019

Cite this page

“Legacy Pharmaceutical Losartan Tablets Recall: NMBA Impurity Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38880-legacy-pharmaceutical-losartan-tablets-recall-nmba-impurity-risk. Based on FDA recall #D-1263-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1263-2019%22&limit=1).

Why it’s dangerous

The recall involves trace amounts of NMBA, a chemical that can be harmful when present in medications. While the exact health risk isn't specified, the presence of this impurity in the active pharmaceutical ingredient raises concerns about potential health effects.

Who’s affected

Prescription patients who have received the recalled 50mg Losartan Potassium Tablets from The Kroger Co. Those with specific health conditions may be at higher risk due to the impurity.

How to tell if you have this one

Check for 50mg Losartan Potassium Tablets, USP, 30-count bottles with NDC 68645-494-54, Lot 181598, and a 02/2021 expiration date. These were distributed by The Kroger Co.

  • Brand
    Legacy Pharmaceutical Packaging LLC
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Contact Manufacturer

    Reach out to Legacy Pharmaceutical Packaging LLC for specific instructions on handling the recalled product.

Where it went and when

Where it was distributed

Distributed in Arizona and Tennessee.

Alaska: not listedAKMaine: not listedMEVermont: not listedVTNew Hampshire: not listedNHWashington: not listedWAIdaho: not listedIDMontana: not listedMTNorth Dakota: not listedNDMinnesota: not listedMNIllinois: not listedILWisconsin: not listedWIMichigan: not listedMINew York: not listedNYRhode Island: not listedRIMassachusetts: not listedMAOregon: not listedORNevada: not listedNVWyoming: not listedWYSouth Dakota: not listedSDIowa: not listedIAIndiana: not listedINOhio: not listedOHPennsylvania: not listedPANew Jersey: not listedNJConnecticut: not listedCTCalifornia: not listedCAUtah: not listedUTColorado: not listedCONebraska: not listedNEMissouri: not listedMOKentucky: not listedKYWest Virginia: not listedWVVirginia: not listedVAMaryland: not listedMDDelaware: not listedDEArizona: yesAZNew Mexico: not listedNMKansas: not listedKSArkansas: not listedARTennessee: yesTNNorth Carolina: not listedNCSouth Carolina: not listedSCDistrict of Columbia: not listedDCOklahoma: not listedOKLouisiana: not listedLAMississippi: not listedMSAlabama: not listedALGeorgia: not listedGAHawaii: not listedHITexas: not listedTXFlorida: not listedFL

FDA distribution: “TN, AZ” States read from FDA’s own wording; “not listed” means the notice does not name it.

States: Arizona, Tennessee.

Recall timeline

FDA published this recall 14 days after the firm started it.

1. Firm started the recall: Apr 24, 201912. FDA classified it Class II: May 1, 201923. Published in FDA’s Enforcement Report: May 8, 201932019
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1263-2019 (April 24, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1263-2019 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA